FGF19 and hepatocellular carcinoma: Although our data are limited to in vitro characterization of HCC cells and will require further validation in animal models and clinical studies, this work provides a rational basis for FGF19/FGFR4 axis for the treatment of sorafenib-resistant HCC, and suggests that inhibition of FGF19/FGFR4 signaling may represent an attractive strategy for overcoming sorafenib resistance in HCC.